P Mortier1,2, G Vilagut1,2, M Ferrer1,2,3, I Alayo1,2,4, R Bruffaerts5, P Cristóbal-Narváez6,7, I Del Cura-González8, J Domènech-Abella6,7, M Felez-Nobrega6,7, B Olaya6,7, J I Pijoan9,10, E Vieta11, V Pérez-Solà3,7,12, R C Kessler13, J M Haro6,14,15, J Alonso1,2,16. 1. Health Services Research Unit, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain. 2. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 3. Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. 4. Pompeu Fabra University, Barcelona, Spain. 5. Center for Public Health Psychiatry, Universitair Psychiatrisch Centrum, KU Leuven, Leuven, Belgium. 6. Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain. 7. CIBER de Salud Mental (CIBERSAM), Madrid, Spain. 8. Research Unit Primary Care Management, Madrid Health Service. (REDISSEC). Universidad Rey Juan Carlos, Madrid, Spain. 9. Clinical Epidemiology Unit, Hospital Universitario Cruces/ OSI EEC, Bilbao, Spain. 10. CIBER Epidemiología y Salud Pública (CIBERESP), Spain. 11. Hospital Clínic, University of Barcelona, IDIBAPS, (CIBERSAM), Barcelona, Spain. 12. Parc de Salut Mar PSMAR, Barcelona, Spain. 13. Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. 14. CIBER Salud Mental (CIBERSAM), Madrid, Spain. 15. Universitat de Barcelona (UB), Barcelona, Spain. 16. Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain.
Abstract
AIMS: To investigate the prevalence of suicidal thoughts and behaviours (STB; i.e. suicidal ideation, plans or attempts) in the Spanish adult general population during the first wave of the Spain coronavirus disease 2019 (COVID-19) pandemic (March-July, 2020), and to investigate the individual- and population-level impact of relevant distal and proximal STB risk factor domains. METHODS: Cross-sectional study design using data from the baseline assessment of an observational cohort study (MIND/COVID project). A nationally representative sample of 3500 non-institutionalised Spanish adults (51.5% female; mean age = 49.6 [s.d. = 17.0]) was taken using dual-frame random digit dialing, stratified for age, sex and geographical area. Professional interviewers carried out computer-assisted telephone interviews (1-30 June 2020). Thirty-day STB was assessed using modified items from the Columbia Suicide Severity Rating Scale. Distal (i.e. pre-pandemic) risk factors included sociodemographic variables, number of physical health conditions and pre-pandemic lifetime mental disorders; proximal (i.e. pandemic) risk factors included current mental disorders and a range of adverse events-experiences related to the pandemic. Logistic regression was used to investigate individual-level associations (odds ratios [OR]) and population-level associations (population attributable risk proportions [PARP]) between risk factors and 30-day STB. All data were weighted using post-stratification survey weights. RESULTS: Estimated prevalence of 30-day STB was 4.5% (1.8% active suicidal ideation; n = 5 [0.1%] suicide attempts). STB was 9.7% among the 34.3% of respondents with pre-pandemic lifetime mental disorders, and 1.8% among the 65.7% without any pre-pandemic lifetime mental disorder. Factors significantly associated with STB were pre-pandemic lifetime mental disorders (total PARP = 49.1%) and current mental disorders (total PARP = 58.4%), i.e. major depressive disorder (OR = 6.0; PARP = 39.2%), generalised anxiety disorder (OR = 5.6; PARP = 36.3%), post-traumatic stress disorder (OR = 4.6; PARP = 26.6%), panic attacks (OR = 6.7; PARP = 36.6%) and alcohol/substance use disorder (OR = 3.3; PARP = 5.9%). Pandemic-related adverse events-experiences associated with STB were lack of social support, interpersonal stress, stress about personal health and about the health of loved ones (PARPs 32.7-42.6%%), and having loved ones infected with COVID-19 (OR = 1.7; PARP = 18.8%). Up to 74.1% of STB is potentially attributable to the joint effects of mental disorders and adverse events-experiences related to the pandemic. CONCLUSIONS: STB at the end of the first wave of the Spain COVID-19 pandemic was high, and large proportions of STB are potentially attributable to mental disorders and adverse events-experiences related to the pandemic, including health-related stress, lack of social support and interpersonal stress. There is an urgent need to allocate resources to increase access to adequate mental healthcare, even in times of healthcare system overload. STUDY REGISTRATION NUMBER: NCT04556565.
AIMS: To investigate the prevalence of suicidal thoughts and behaviours (STB; i.e. suicidal ideation, plans or attempts) in the Spanish adult general population during the first wave of the Spain coronavirus disease 2019 (COVID-19) pandemic (March-July, 2020), and to investigate the individual- and population-level impact of relevant distal and proximal STB risk factor domains. METHODS: Cross-sectional study design using data from the baseline assessment of an observational cohort study (MIND/COVID project). A nationally representative sample of 3500 non-institutionalised Spanish adults (51.5% female; mean age = 49.6 [s.d. = 17.0]) was taken using dual-frame random digit dialing, stratified for age, sex and geographical area. Professional interviewers carried out computer-assisted telephone interviews (1-30 June 2020). Thirty-day STB was assessed using modified items from the Columbia Suicide Severity Rating Scale. Distal (i.e. pre-pandemic) risk factors included sociodemographic variables, number of physical health conditions and pre-pandemic lifetime mental disorders; proximal (i.e. pandemic) risk factors included current mental disorders and a range of adverse events-experiences related to the pandemic. Logistic regression was used to investigate individual-level associations (odds ratios [OR]) and population-level associations (population attributable risk proportions [PARP]) between risk factors and 30-day STB. All data were weighted using post-stratification survey weights. RESULTS: Estimated prevalence of 30-day STB was 4.5% (1.8% active suicidal ideation; n = 5 [0.1%] suicide attempts). STB was 9.7% among the 34.3% of respondents with pre-pandemic lifetime mental disorders, and 1.8% among the 65.7% without any pre-pandemic lifetime mental disorder. Factors significantly associated with STB were pre-pandemic lifetime mental disorders (total PARP = 49.1%) and current mental disorders (total PARP = 58.4%), i.e. major depressive disorder (OR = 6.0; PARP = 39.2%), generalised anxiety disorder (OR = 5.6; PARP = 36.3%), post-traumatic stress disorder (OR = 4.6; PARP = 26.6%), panic attacks (OR = 6.7; PARP = 36.6%) and alcohol/substance use disorder (OR = 3.3; PARP = 5.9%). Pandemic-related adverse events-experiences associated with STB were lack of social support, interpersonal stress, stress about personal health and about the health of loved ones (PARPs 32.7-42.6%%), and having loved ones infected with COVID-19 (OR = 1.7; PARP = 18.8%). Up to 74.1% of STB is potentially attributable to the joint effects of mental disorders and adverse events-experiences related to the pandemic. CONCLUSIONS: STB at the end of the first wave of the Spain COVID-19 pandemic was high, and large proportions of STB are potentially attributable to mental disorders and adverse events-experiences related to the pandemic, including health-related stress, lack of social support and interpersonal stress. There is an urgent need to allocate resources to increase access to adequate mental healthcare, even in times of healthcare system overload. STUDY REGISTRATION NUMBER: NCT04556565.
Authors: Michelle Torok; Jin Han; Simon Baker; Aliza Werner-Seidler; Iana Wong; Mark E Larsen; Helen Christensen Journal: Lancet Digit Health Date: 2019-11-29
Authors: Ronald C Kessler; Patcho N Santiago; Lisa J Colpe; Catherine L Dempsey; Michael B First; Steven G Heeringa; Murray B Stein; Carol S Fullerton; Michael J Gruber; James A Naifeh; Matthew K Nock; Nancy A Sampson; Michael Schoenbaum; Alan M Zaslavsky; Robert J Ursano Journal: Int J Methods Psychiatr Res Date: 2013-12 Impact factor: 4.035
Authors: David Gunnell; Louis Appleby; Ella Arensman; Keith Hawton; Ann John; Nav Kapur; Murad Khan; Rory C O'Connor; Jane Pirkis Journal: Lancet Psychiatry Date: 2020-04-21 Impact factor: 27.083
Authors: Marina Moreno Martínez; María Isabel Fernández-Cano; Maria Feijoo-Cid; Clara Llorens Serrano; Albert Navarro Journal: Saf Sci Date: 2021-09-16 Impact factor: 6.392
Authors: Farah Yasmin; Hafsa Nazir Jatoi; Muhammad Saif Abbasi; Muhammad Sohaib Asghar; Sarush Ahmed Siddiqui; Hamza Nauman; Abdullah Khan Khattak; Muhammad Tanveer Alam Journal: Front Psychol Date: 2022-03-15
Authors: J Alonso; G Vilagut; I Alayo; M Ferrer; F Amigo; A Aragón-Peña; E Aragonès; M Campos; I Del Cura-González; I Urreta; M Espuga; A González Pinto; J M Haro; N López Fresneña; A Martínez de Salázar; J D Molina; R M Ortí Lucas; M Parellada; J M Pelayo-Terán; A Pérez Zapata; J I Pijoan; N Plana; M T Puig; C Rius; C Rodriguez-Blazquez; F Sanz; C Serra; R C Kessler; R Bruffaerts; E Vieta; V Pérez-Solá; P Mortier Journal: Epidemiol Psychiatr Sci Date: 2022-04-29 Impact factor: 7.818
Authors: José Juan Pereyra-Rodríguez; Giovana Fernanda Osorio-Gómez; Juan Ortiz-Álvarez; Juan Carlos Hernández-Rodríguez; Antonio José Durán-Romero; Julián Conejo-Mir Sánchez Journal: Arch Dermatol Res Date: 2022-09-15 Impact factor: 3.033
Authors: Anna Monistrol-Mula; Mireia Felez-Nobrega; Maria Victoria Moneta; Elena Condominas; Gemma Vilagut; Laia Martin-Iñigo; Joan Domènech-Abella; Albert Sánchez-Niubó; Philippe Mortier; Paula Cristóbal-Narváez; Beatriz Olaya; Jordi Alonso; Josep Maria Haro Journal: J Affect Disord Date: 2022-09-01 Impact factor: 6.533
Authors: V Pérez; M Elices; G Vilagut; E Vieta; J Blanch; E Laborda-Serrano; B Prat; F Colom; D Palao; J Alonso Journal: Eur Neuropsychopharmacol Date: 2021-11-19 Impact factor: 5.415